French biotech jumps after gaining license to regulatory T cell patents

9 December 2016

A biotechnology company developing personalized cellular immunotherapies using regulatory T cells (Tregs) to treat severe chronic inflammatory and autoimmune diseases has announced an exclusive worldwide licensing agreement with a research institute.

The agreement, financial terms of which have not been disclosed, will see the French biotech, TxCell (Euronext Paris: TXCL), gaining the license to two patent families filed by the Center for Research in Transplantation and Immunology (CRTI).

"TxCell, by obtaining an exclusive license on patents covering a new CD8+ Treg cell sub-population, adds a new pillar to its patent portfolio and further strengthens TxCell’s position as the international Treg leading expert"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK